We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Idaho Technology Becomes BioFire Diagnostics

By LabMedica International staff writers
Posted on 11 Sep 2012
Idaho Technology, Inc. More...
has changed its corporate name to BioFire Diagnostics, Inc. (Salt Lake City, UT, USA) to more accurately reflect its growing breadth of services in molecular diagnostics. The company also re-launched its website to reveal its new branding.

BioFire Diagnostics will continue to focus on its FilmArray pathogen detection system to develop multiplex diagnostic tests for various clinical applications. The FilmArray Respiratory Panel (RP) is US Food and Drug Administration (FDA; Silver Spring, MD, USA)-cleared for 20 viral and bacterial respiratory pathogens. The company now provides the only FDA-cleared clinical diagnostic test for 8 of the 20 organisms in its panel.

The company is continuing to develop a broader test menu for its FilmArray system, including a blood culture ID panel, gastrointestinal panel, and a meningitis panel. BioFire is also working on reliable and sensitive biosurveillance products such as its polymerase chain reaction (PCR)-based biodetection system RAZOR EX and the FilmArray BioSurveillance system. With over 70 patents related to polymerase chain reaction (PCR), the company has used its extensive patent portfolio to successfully market nearly 200 products to the clinical, research, and military markets.

The diagnostic respiratory panel, FilmArray RP operates on the user-friendly FilmArray system, for hospital-based clinical laboratories in the US and EU.

Kirk Ririe, CEO of BioFire Diagnostics said, "We have established strong momentum in the diagnostics marketplace and the new branding under BioFire Diagnostics better reflects the markets we serve. We believe we are in an excellent position to continue building our business by driving growth of our broad molecular diagnostic product portfolio."

BioFire collaborates with various US governmental agencies including the Department of Health and Human Services and the Department of Defense. Additionally, researchers, medical technicians, law enforcement officers, and soldiers in the field use company devices to detect or study disease-causing organisms.

Related Links:
BioFire Diagnostics, Inc.
US Food and Drug Administration


New
Gold Member
Automatic Hematology Analyzer
CF9600
New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Clinical Informatics Platform
CLARION™
New
Repetitive Pipette
VWR® Stepper Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.